Bristol Myers Squibb is hoping that arlocabtagene autoleucel, its CAR-T cell therapy directed at GPRC5D, could provide a competitive boost over bispecific antibodies with the same target given its potentially lower incidence of on-target toxicities, which may boil down to differences between the two modalities.
ASH: Better Safety Could Boost BMS’s Anti-GPRC5D CAR-T
BMS presented Phase I data for arlocabtagene autoleucel, showing a strong median PFS and lower incidence and severity of trouble swallowing, a common side effect of anti-GPRC5D drugs.
